{"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 3.0 - 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m\\^2, tablets, orally, on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles).","id":"BG000","title":"Arm A: Ixazomib 3.0 - 3.7 mg"},{"description":"Ixazomib 3.0 - 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m\\^2, tablets, orally, on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally, on Days 1-4 for in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles).","id":"BG001","title":"Arm B: Ixazomib 3.0 - 5.5 mg"},{"description":"Ixazomib 3.0 - 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m\\^2, tablets, orally, on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles).","id":"BG002","title":"Arm C: Ixazomib 3.0 - 4.0 mg"},{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m\\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles).","id":"BG003","title":"Arm D: Ixazomib 4.0 mg"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.68","value":"74.2"},{"groupId":"BG001","spread":"4.79","value":"74.3"},{"groupId":"BG002","spread":"4.27","value":"76.3"},{"groupId":"BG003","spread":"9.66","value":"73.2"},{"groupId":"BG004","spread":"5.60","value":"74.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"31"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"<75"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"30"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":">=75"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"38"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Missing"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"56"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Not Hispanic or Latino"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"57"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"15"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"30"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.872","value":"162.24"},{"groupId":"BG001","spread":"12.087","value":"162.68"},{"groupId":"BG002","spread":"11.413","value":"164.50"},{"groupId":"BG003","spread":"16.897","value":"160.50"},{"groupId":"BG004","spread":"11.615","value":"162.65"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"59"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Height data was only available for 11, 33, 9 and 6 participants in the Arms A, B, C and D respectively.","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.389","value":"70.58"},{"groupId":"BG001","spread":"16.642","value":"73.43"},{"groupId":"BG002","spread":"20.532","value":"72.77"},{"groupId":"BG003","spread":"21.404","value":"66.97"},{"groupId":"BG004","spread":"16.509","value":"72.17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"61"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight at Baseline","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.1426","value":"1.782"},{"groupId":"BG001","spread":"0.2638","value":"1.813"},{"groupId":"BG002","spread":"0.3337","value":"1.799"},{"groupId":"BG003","spread":"0.3650","value":"1.718"},{"groupId":"BG004","spread":"0.2638","value":"1.795"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"59"}],"units":"Participants"}]}],"description":"Body Surface Area (m\\^2) = square root \\[height (cm) x weight (kg) / 3600\\].","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Body Surface Area data was only available for 11, 33, 9 and 6 participants in the Arms A, B, C and D respectively.","title":"Body Surface Area at Baseline","unitOfMeasure":"m^2"}],"populationDescription":"The safety population consisted of participants who received at least 1 dose of any study drug."}